virus
virus
one
smallest
biolog
entiti
infect
life
form
bacteria
fungi
anim
plant
tobacco
mosaic
viru
first
viru
identifi
sinc
virus
investig
detail
although
probabl
million
virus
exist
discov
latest
among
cluster
virus
mollusc
discov
late
among
virus
pathogen
human
one
could
count
influenza
measl
whoop
cough
plagu
polio
name
random
number
augment
occasion
new
zoonot
virus
make
jump
anim
host
infect
human
creat
new
diseas
notabl
among
human
immunodefici
viru
hiv
aros
simian
immunodefici
viru
began
infect
human
around
zika
viru
epidem
affect
part
america
time
whose
sourc
believ
primat
africa
new
virus
aris
human
bodi
prepar
defens
mechan
could
lead
widespread
epidem
pandem
spanish
flu
one
instanc
spread
rapidli
across
world
result
million
also
estim
million
fatal
tabl
provid
glimps
outstand
viral
epidem
centuri
show
pathogen
viral
diseas
even
understand
date
human
bodi
defend
invad
foreign
pathogen
elabor
immun
respons
system
invad
identifi
systemat
elimin
long
histori
effort
aid
process
combat
viral
menac
landmark
achiev
list
tabl
much
need
done
fight
recurr
new
epidem
current
effort
ration
design
antivir
vaccin
augment
effort
base
understand
microbiolog
genom
virus
human
immun
system
recount
briefli
action
organ
virus
exist
individu
particl
refer
virion
virion
consist
protein
shell
call
capsid
genom
viru
insid
case
virus
also
lipid
envelop
cover
capsid
virus
call
dna
virus
carri
singlestrand
doublestrand
dna
genom
virus
call
rna
virus
may
carri
doublestrand
rna
singlestrand
posit
neg
sens
rna
genom
genom
could
continu
strand
case
dengu
could
separ
piec
one
constitu
gene
case
influenza
genom
refer
segment
genom
gene
group
structur
nonstructur
structur
gene
contribut
make
capsid
viral
coat
form
mani
ident
protein
subunit
may
consist
one
protein
group
togeth
take
form
icosahedr
helic
prolat
nonstructur
gene
function
replic
genom
among
function
viru
attack
cell
part
surfac
protein
attach
cell
surfac
segment
call
receptor
fuse
interior
cell
process
known
endocytosi
insid
cell
outer
layer
virion
remov
viral
host
enzym
viral
genom
releas
viral
gene
involv
synthesi
viral
messeng
rna
mrna
viral
protein
synthesi
replic
viral
genom
use
machineri
host
cell
produc
multipl
copi
replic
may
error
copi
nucleotid
result
mutat
gene
dna
virus
abil
use
error
correct
enzym
undo
damag
rna
virus
machineri
accumul
error
rapidli
estim
rna
virus
accumul
error
rate
per
nucleotid
per
replic
virus
nucleotid
long
genom
influenza
dengu
virus
accumul
error
rate
nucleotid
per
replic
dna
virus
hand
accumul
error
rate
therefor
much
stabl
accumul
error
call
genet
drift
may
lead
creation
new
strain
viru
method
gener
new
strain
reassort
segment
genom
whole
gene
may
exchang
anoth
homolog
strain
rare
recombin
part
gene
may
exchang
similar
segment
anoth
homolog
strain
replic
product
move
endoplasm
reticulum
golgi
apparatu
differ
element
put
togeth
assembl
viru
particl
matur
virion
releas
host
cell
lysi
process
viral
product
break
cell
membran
readi
next
infect
host
cell
destroy
virus
acquir
lipid
envelop
lysi
process
organ
equip
degre
immun
invad
pathogen
microorgan
immun
consid
two
partsdinn
immun
adapt
immun
innat
immun
provid
dri
outer
skin
mucou
guinea
declar
ebola
free
success
vaccin
drive
membran
certain
open
like
mouth
nostril
uterin
passag
etc
bodi
temperatur
highli
acid
environ
stomach
mani
other
act
prevent
pathogen
microorgan
harm
host
necessarili
specif
particular
pathogen
varieti
pathogen
microorgan
may
enter
bodi
cut
bruis
ingest
phagocyt
macrophag
dendrit
cell
final
elimin
adapt
immun
bodi
respons
specif
pathogen
refer
antigen
pass
innat
immun
barrier
variou
mean
adapt
immun
two
typesdhumor
immun
root
blood
serum
bodi
fluid
known
humor
ancient
time
cellbas
immun
case
immun
respons
mediat
primarili
two
cell
typesdblymphocyt
bcell
tlymphocyt
tcell
produc
bone
marrow
bcell
matur
bone
marrow
leav
express
antigenbind
receptor
call
antibodi
uniqu
bcell
membran
tlymphocyt
tcell
move
bone
marrow
thymu
matur
leav
tcell
express
uniqu
membranebound
molecul
call
tcell
receptor
also
bind
antigen
certain
condit
antibodi
receptor
encod
specif
gene
undergo
random
rearrang
creat
differ
antibodi
everi
bcell
tcell
thousand
antibodi
receptor
surfac
cell
uniqu
ident
antibodi
collect
would
bcell
tcell
produc
bone
marrow
number
reduc
extent
filter
prevent
autoimmun
threat
antibodi
antibodi
bind
antigen
extrem
specif
antibodi
bond
specif
antigen
even
chang
one
amino
acid
antigen
nullifi
bond
avail
million
band
tcell
antibodi
provid
divers
specif
antibodyantigen
bind
multifari
pathogen
bcell
receptor
recogn
foreign
antigen
bcell
bcell
yet
encount
antigen
split
immedi
encount
antigen
memori
bcell
effector
bcell
progeni
bcell
ident
membranebound
receptor
naiv
bcell
memori
bcell
surviv
much
longer
bcell
effector
bcell
live
short
period
releas
antibodi
high
rate
per
second
first
encount
antigen
immun
respons
take
day
start
peak
day
second
attack
respons
occur
fast
day
intens
high
vaccin
prime
bodi
kind
respons
tcell
also
similar
respons
profil
two
subtyp
tcellsdthelp
cell
h
tcytotox
cell
c
thelper
cell
associ
membran
glycoprotein
tcytotox
cell
membran
glycoprotein
associ
tcell
recogn
antigen
coupl
special
protein
molecul
known
major
histocompat
complex
mhc
molecul
display
surfac
cell
human
mhc
molecul
express
certain
hla
human
leukocyt
antigen
allel
contain
cleft
distal
end
membran
contain
peptid
two
main
class
mhcdmhc
class
express
almost
vertebr
nucleat
cell
mhc
class
ii
express
antigen
present
cell
cell
like
macrophag
dendrit
etc
ingest
invad
antigen
phagocytosi
endocytosi
degrad
complex
antigen
small
peptid
peptid
get
attach
mhc
class
ii
molecul
rise
surfac
cell
target
h
cell
trigger
mechan
eventu
elimin
antigen
invad
host
cell
replic
get
peptid
attach
endoplasm
reticulum
mhc
class
molecul
move
cell
surfac
c
cell
recogn
mhcipeptid
complex
prolifer
differenti
effector
cell
known
cytotox
tlymphocyt
ctl
ctl
monitor
affect
cell
kill
attach
degrad
peptid
mhc
molecul
govern
conform
cleft
distal
end
hla
give
rise
mhc
highli
polymorph
polygen
hla
databas
list
hla
class
ii
molecul
alon
allel
differ
individu
popul
understand
experiment
approach
determin
antigen
tradit
vaccin
effect
mhcpeptid
bond
test
prohibit
timeconsum
expens
process
comput
techniqu
coupl
robust
algorithm
determin
bind
affin
peptid
mhc
molecul
becom
reason
approach
still
dearth
good
data
mani
allel
make
popul
hla
profil
depend
good
model
homolog
molecular
dock
structur
data
remain
imper
bioinformat
therefor
lead
current
search
effect
vaccin
target
vaccin
relat
adapt
immun
specif
pathogen
address
vital
import
success
vaccin
program
rna
virus
influenza
mutat
rapidli
vaccin
develop
influenza
strain
one
year
may
work
strain
next
year
center
diseas
control
prevent
usa
prescrib
differ
vaccin
everi
year
combat
flu
strain
expect
would
major
trend
year
drug
face
hurdl
drug
relenza
develop
influenza
render
useless
year
specif
mutat
flu
strain
current
favorit
oseltamivir
drug
market
tamiflu
also
report
face
resist
part
unit
state
japan
due
viral
mutat
vaccin
devis
yet
common
viral
diseas
like
dengu
rotaviru
intestin
viral
infect
kill
million
infant
year
wit
repeat
vaccin
failur
albeit
complic
postvaccin
situat
dna
virus
much
stabl
vaccin
activ
far
longer
period
reason
smallpox
could
erad
world
almost
poliofre
human
papillomaviru
address
commerci
avail
vaccin
success
vaccin
therefor
critic
depend
upon
natur
viru
genom
content
understand
antigen
properti
immun
respons
evok
viral
protein
fundament
understand
viru
action
vaccin
use
present
gener
one
sever
type
first
attenu
liveattenu
viru
viral
genom
alter
viru
becom
less
virul
harmless
still
elicit
immun
respons
vaccin
measl
mump
rubella
sever
viral
diseas
type
vaccin
problem
sometim
mutat
genom
make
revert
back
virul
form
infect
human
host
anoth
convent
vaccin
inactiv
varieti
genom
viru
remov
kill
heat
chemic
treatment
empti
capsid
use
gener
immun
respons
varieti
influenza
polio
vaccin
manufactur
manner
depend
upon
degre
treatment
vaccin
may
requir
one
booster
shot
retain
activ
also
sinc
entir
virion
shell
use
vaccin
caus
allergen
reaction
suscept
person
third
type
vaccin
vlp
viruslik
particl
instanc
surfac
protein
virion
selfassembl
structur
like
origin
viru
construct
elicit
immun
respons
often
aid
adjuv
vlp
vaccin
difficult
design
manufactur
date
vlp
licens
hepat
e
viru
human
papillomaviru
interest
applic
idea
yet
experiment
stage
report
recent
group
centr
infecti
diseas
research
seattl
unit
state
creat
malaria
parasit
vaccin
genet
delet
three
gene
express
preerythrocyt
stage
pseudomona
falciparum
becom
incap
caus
infect
vaccin
found
evok
good
immun
respons
malari
infect
full
safeti
mice
model
test
human
volunt
trial
plan
tradit
approach
vaccin
discuss
requir
long
develop
period
result
alway
satisfactori
apart
everpres
threat
attenu
viral
vaccin
mutat
pathogen
form
tradit
vaccin
design
gener
use
whole
protein
viru
coat
antigen
evok
immun
respons
also
sometim
caus
allergi
human
type
autoimmun
reaction
also
vaccin
develop
great
cost
suitabl
one
commun
may
work
anoth
peopl
suscept
differ
strain
viru
instanc
human
papillomavirus
occur
mani
type
type
combin
afflict
human
univers
rapid
advanc
recent
decad
inform
technolog
highthroughput
sequenc
dna
rna
genom
complet
initi
stage
human
genom
project
better
understand
immunogenet
develop
immunoinformat
provid
valuabl
insight
human
immun
respons
work
guard
elimin
foreign
pathogen
gain
entri
bodi
led
develop
scienc
vaccinom
seek
util
understand
bodi
immun
reaction
precis
target
part
viru
antigen
determin
enabl
immun
respons
kill
viru
along
data
person
dna
vaccinom
envisag
ideal
scenario
admittedli
distant
futur
genet
viral
inform
tailor
vaccin
would
best
suit
individualdperson
immun
safe
effici
effect
everyon
without
worri
side
effect
new
disciplin
bioinformat
becom
essenti
tool
achiev
goal
bioinformat
play
central
role
new
paradigm
vaccin
design
bioinformat
interdisciplinari
field
bring
togeth
concept
biolog
mathemat
statist
comput
scienc
provid
quantit
basi
understand
classifi
model
queri
analyz
biolog
data
develop
bioinformat
possibl
construct
extens
databas
variou
biolog
quantiti
dna
rna
protein
sequenc
analyz
huge
quantiti
accumul
data
similar
dissimilar
understand
newli
sequenc
sequenc
interrelationship
gain
new
insight
exampl
learnt
fractal
natur
dna
sequenc
newli
evolv
scienc
molecular
evolut
would
scarc
possibl
without
bioinformat
recent
progress
wide
dissemin
internet
resourc
enabl
sever
tool
bioinformat
analys
avail
univers
access
across
web
develop
spur
innov
progress
biolog
data
analys
contribut
significantli
new
way
analyz
viral
structur
design
vaccin
wide
access
preemin
resourc
bioinformat
provid
nation
center
biotechnolog
inform
ncbi
nation
institut
health
unit
state
european
molecular
biolog
laboratori
embl
extens
databas
biolog
inform
analyt
softwar
databas
includ
genbank
repositori
sequenc
ncbi
augment
submiss
research
new
sequenc
data
protein
data
bank
pdb
contain
inform
protein
sequenc
structur
pubchem
contain
data
chemic
structur
sever
databas
equival
record
access
databas
maintain
embl
ddbj
dna
databank
japan
part
intern
nucleotid
sequenc
databas
collabor
insdc
nucleotid
sequenc
record
evolut
organ
directli
biolog
inform
thu
insdc
constitut
invalu
resourc
studi
live
system
initi
submiss
databas
mainli
region
research
distribut
among
collabor
institut
approv
format
worldwid
access
aid
compar
homolog
studi
sequenc
popular
softwar
tool
avail
institut
sourc
includ
blast
basic
local
align
search
tool
clustalw
multipl
align
sequenc
view
structur
avail
protein
structur
data
mani
other
complement
effort
major
institut
numer
bioinformat
tool
develop
specif
task
avail
across
web
cover
select
later
section
detail
bioinformat
provid
tool
analyz
divers
sequenc
data
practic
consider
perforc
set
limit
achiev
time
person
vaccin
approach
ideal
vaccinom
still
far
cri
suboptim
approach
vaccinom
avoid
individu
human
genom
part
optim
viral
inform
revers
vaccinolog
yield
result
revers
vaccinolog
model
part
vaccinom
regim
use
bioinformat
techniqu
screen
entir
genom
pathogen
determin
gene
could
lead
good
epitop
peptid
antigen
antibodi
actual
bind
protein
surfac
situat
select
proteinspeptid
synthet
produc
test
anim
model
date
techniqu
use
bacteri
pathogen
first
human
vaccin
devis
use
method
serogroup
b
meningococcu
caus
mening
although
sever
trial
experiment
entir
exercis
took
year
wherea
tradit
vaccin
develop
method
normal
take
decad
case
particular
pathogen
difficulti
use
tradit
method
autoimmun
threat
use
bioinformat
method
prime
import
identifi
surfac
antigen
could
use
design
vaccin
extend
revers
vaccinolog
model
cover
viral
diseas
mani
vaccin
propos
larg
number
undergo
field
trial
variou
phase
essenti
method
case
scan
viral
genom
surfac
protein
b
analyz
surfac
protein
predict
best
epitop
region
c
ensur
epitop
surfac
situat
test
autoimmun
threat
see
schemat
fig
success
complet
step
viral
peptid
match
epitop
requir
recommend
vaccin
target
prepar
vitro
vivo
test
field
trial
launch
anim
human
model
whose
result
final
determin
suitabl
peptid
vaccin
among
first
case
report
success
use
model
virul
canin
paroviru
stimul
similar
search
malaria
swine
flu
diseas
anim
propos
advanc
ovarian
breast
cancer
benefit
peptid
deriv
cell
surfaceassoci
mucin
gene
initi
field
trial
shown
peptid
antigen
vaccin
lymphocyt
choriomening
viru
provid
adequ
antivir
respons
mixtur
four
peptid
nonsmal
cell
lung
cancer
found
safe
capabl
gener
strong
tcell
respons
current
author
ad
step
four
mention
earlier
ration
design
peptid
vaccin
viz
conserv
segment
issu
viral
genom
especi
rna
viral
genom
undergo
rapid
mutat
chang
render
drug
vaccin
one
strain
viru
rapidli
obsolet
minim
risk
first
step
taken
analyz
mani
viral
protein
sequenc
possibl
similar
dissimilar
determin
segment
remain
essenti
conserv
even
though
viral
genom
undergo
numer
mutat
chang
procedur
adopt
make
analysi
anoth
applic
bioinformat
techniqu
almost
univers
approach
determin
similar
dissimilar
set
biomolecular
sequenc
particular
viru
depend
upon
quit
sophist
softwar
determin
segment
similar
across
variou
sequenc
introduc
gap
maxim
predefin
measur
similar
techniqu
sequenc
align
enabl
discoveri
essenti
similar
sequenc
determin
evolutionari
relationship
softwar
clustalw
align
mega
molecular
evolutionari
genet
analysi
determin
phylogenet
relationship
popular
purpos
howev
model
depend
gap
assess
score
done
determin
best
fit
align
multipl
sequenc
also
align
mani
sequenc
take
lot
comput
time
could
rapidli
becom
ineffici
handl
hundr
sequenc
align
techniqu
reliabl
sequenc
align
close
relat
wherea
result
diverg
sequenc
alway
reliabl
therefor
often
use
altern
approach
alignmentfre
techniqu
bare
coupl
decad
old
becom
increasingli
preval
sever
method
propos
comput
sequenc
differ
concept
kmerword
frequenc
base
group
batch
analyz
techniqu
involv
analys
substr
within
sequenc
inform
theori
anoth
techniqu
gather
lot
momentum
initi
impetu
provid
graphic
represent
dna
sequenc
higher
dimens
assess
quantit
provid
measur
degre
similar
dissimilar
sequenc
quantit
measur
comput
either
geometr
mean
matrix
method
see
video
onlin
version
http
brief
introduct
model
specif
geometr
approach
intuit
simpl
dna
rna
sequenc
n
nucleotid
one
start
origin
twodimension
cartesian
coordin
system
proce
one
step
neg
xdirect
adenin
one
step
posit
ydirect
cytosin
one
step
posit
xdirect
guanin
one
step
neg
ydirect
thymin
uracil
rna
success
base
sequenc
start
begin
trace
graph
xyplain
reflect
base
distribut
sequenc
base
x
coordin
one
defin
weight
center
mass
graph
radiu
distanc
origin
center
mass
q
uniqu
sequenc
form
kind
descriptor
sequenc
definit
also
allow
distanc
two
sequenc
measur
enabl
phylogenet
tree
drawn
show
relationship
sequenc
close
knit
famili
beauti
graph
radiu
defin
earlier
ident
valu
g
r
impli
ident
sequenc
sequenc
segment
enabl
current
author
trace
movement
avian
flu
viral
strain
across
countri
determin
incid
recombin
event
influenza
hemagglutinin
method
comput
sequenc
descriptor
mainli
matrix
method
eigenvalu
especi
lead
eigenvalu
defin
matrix
serv
identifi
sequenc
seen
review
list
read
select
peptid
segment
base
research
criteria
eg
sequenc
conserv
match
solvent
access
profil
select
criteria
check
protein
structur
data
retain
segment
surfac
exposur
solvent
access
test
identifi
segment
reject
auto
immun
potenti
final
list
recommend
peptid
segment
concept
graphic
represent
extend
sever
author
cover
protein
sequenc
slightli
complic
sinc
amino
acid
contend
adopt
virtual
rectangular
represent
amino
acid
assign
one
axi
protein
sequenc
plot
imaginari
system
take
one
step
time
along
axi
specifi
amino
acid
sequenc
plot
curv
hyperspac
protein
sequenc
n
amino
acid
could
defin
weight
center
mass
n
graph
radiu
p
r
suitabl
parameter
describ
paper
found
identifi
ident
protein
sequenc
p
r
valu
ident
techniqu
develop
current
author
group
determin
extent
varianc
differ
strain
viru
movement
ident
strain
across
countri
segment
rna
protein
sequenc
remain
conserv
across
mani
mutat
mani
procedur
ration
design
peptid
vaccin
encompass
follow
step
see
schemat
fig
select
surfac
situat
protein
viral
coat
exampl
hemagglutinin
neuraminidas
influenza
protein
human
papillomaviru
hpv
b
scan
mani
viral
protein
sequenc
possibl
determin
segment
chang
least
p
r
valu
window
particular
segment
length
chang
least
sequenc
segment
length
amino
acid
conson
cleft
size
mhc
class
class
ii
protein
c
analyz
protein
sequenc
averag
solvent
access
score
determin
segment
qualifi
potenti
surfac
peptid
peptid
select
step
analyz
appropri
softwar
predict
potenti
linear
conform
epitop
e
peptid
pass
test
next
check
protein
structur
avail
ensur
select
peptid
inde
lie
surfac
cover
neighbor
protein
multimer
quaternari
structur
f
peptid
qualifi
test
test
next
autoimmun
threat
blast
analysi
compar
identifi
peptid
human
protein
sequenc
peptid
pass
rigor
test
expect
target
vaccin
elicit
human
immun
respons
exampl
protein
identifi
peptid
region
influenza
neuraminidas
protein
given
fig
video
onlin
version
http
sever
consider
howev
peptid
classifi
vaccin
question
adequaci
immun
respons
often
adjuv
requir
augment
immun
recognit
process
need
enabl
peptid
carrier
protein
ensur
fold
shape
therefor
evad
antibodi
bind
envisag
last
least
may
necessari
one
peptid
vaccin
inject
time
best
result
socal
multival
vaccin
approach
howev
major
bioinformat
step
taken
outlin
earlier
help
narrow
possibl
peptid
expedit
vaccin
develop
process
far
beyond
tradit
vaccin
develop
techniqu
allow
bioinformat
softwar
use
often
ration
design
peptid
vaccin
outlin
earlier
briefli
mention
later
one
import
step
analyz
invad
pathogen
possibl
vaccin
target
identifi
epitop
region
accumul
databas
identifi
epitop
antigen
establish
start
point
determin
potenti
epitop
new
antigen
determin
analys
exercis
done
use
differ
methodolog
includ
neural
network
qsar
quantit
structur
activ
relationship
among
mani
epitop
predict
softwar
wide
use
webbas
server
follow
iedb
immun
epitop
databas
analysi
resourc
provid
collect
tool
predict
analysi
immun
epitop
tcell
bcell
epitop
predict
tool
softwar
suit
predict
bind
affin
mhc
class
class
ii
molecul
includ
tool
predict
intrins
potenti
peptid
tcell
epitop
base
proteasom
process
transport
associ
process
tap
mhc
class
bind
bcell
tool
predict
linear
epitop
includ
ellipro
analys
protein
antigen
structur
term
complex
geometr
shape
predict
possibl
linear
conform
epitop
import
analys
tool
iedb
popul
coverag
fraction
individu
respond
given
set
epitop
predict
base
hla
genotyp
frequenc
assum
target
popul
abcpr
web
server
use
artifici
neural
network
predict
bcell
epitop
antigen
sequenc
train
set
use
bcell
epitop
nonbcel
epitop
random
peptid
maximum
length
residu
achiev
accuraci
epitop
predict
vaxijen
first
onlin
server
alignmentfre
predict
protect
antigen
base
physicochem
properti
protein
deriv
princip
amino
acid
properti
protein
sequenc
use
bacteri
viral
tumor
protein
dataset
design
model
protein
antigen
predict
test
set
show
predict
accuraci
mhcpred
use
addit
method
predict
bind
affin
peptid
mhc
class
class
ii
molecul
also
predict
tap
bind
affin
epijen
predict
bind
affin
mhc
class
molecul
tcell
epitop
predict
take
three
type
interact
account
interact
individu
amino
acid
bind
site
interact
adjac
everi
second
amino
acid
effect
bind
model
consid
stage
antigen
present
mhc
class
includ
proteasom
cleavag
tap
bind
predict
effect
epitop
result
often
concis
predict
small
percent
possibl
peptid
epitop
server
offer
tool
predict
cytotox
tlymphocyt
ctl
epitop
protein
sequenc
use
artifici
neural
network
predict
ctl
epitop
mhc
class
bind
proteasom
cleavag
method
also
integr
tap
transport
effici
predict
cover
mhc
super
type
train
set
known
mhc
class
ligand
one
main
consider
effect
antibodi
bind
epitop
access
antigen
import
therefor
determin
solvent
access
hydrophob
index
sever
softwar
avail
determin
index
sabl
itass
hhpred
etc
commonli
use
purpos
provid
indic
amino
acidwis
surfac
access
residu
accuraci
excess
coupl
epitop
predict
data
provid
indic
epitop
could
access
antibodyantigen
bind
structur
inform
viral
surfac
protein
consider
vaccin
design
use
ensur
epitop
consid
surfac
situat
asa
profil
comput
cover
neighbor
protein
multimer
structur
exampl
influenza
hemagglutinin
neuraminidas
inform
also
requir
ellipro
analysi
especi
conform
epitop
domin
mhc
class
ii
epitop
virus
human
papillomaviru
commonli
use
softwar
view
structur
data
avail
ncbi
websit
pymol
rasmol
power
molecular
graphic
visual
tool
capabl
highlight
segment
user
interest
fig
show
one
monomer
structur
quadromer
influenza
neuraminidas
protein
view
softwar
fig
space
fill
model
neuraminidas
protein
show
surfac
expos
conserv
peptid
segment
shown
differ
color
one
monom
cyan
quaternari
structur
peptid
seen
video
space
fill
model
neuraminidas
protein
show
surfac
expos
conserv
peptid
segment
shown
differ
color
one
monom
cyan
quaternari
structur
peptid
seen
video
onlin
version
http
reproduc
ghosh
nandi
p
comput
analysi
determin
highli
conserv
surfac
expos
segment
avian
flu
swine
flu
neuraminidas
bmc
structur
biolog
fig
thu
numer
tool
avail
new
bioinformat
era
tool
server
constantli
ad
user
make
best
use
avail
data
inform
analyt
deriv
end
result
desir
avail
bioinformat
tool
advanc
made
genet
immunogenom
recombin
dna
technolog
other
provid
impetu
design
new
age
peptid
vaccin
consider
advantag
tradit
vaccin
product
manufactur
synthet
peptid
like
chemic
stringent
puriti
qualiti
control
product
peptid
simpl
fast
costeffect
problem
associ
biolog
contamin
antigen
remov
product
typic
stabl
normal
storag
condit
peptid
prime
avoid
allerg
autoimmun
respons
ideal
principl
design
individu
need
howev
problem
well
peptid
poor
immunogen
requir
adjuv
immun
stimul
effect
also
suscept
enzymat
degrad
choic
epitop
crucial
step
design
peptid
vaccin
epitop
abl
induc
strong
longlast
humor
cellular
immun
pathogen
sometim
immunodomin
type
desir
ultim
chosen
epitop
need
highli
conserv
cover
varieti
viral
strain
mixtur
sever
epitop
requir
vaccin
overal
howev
product
peptid
vaccin
lead
improv
time
cost
initi
screen
possibl
vaccin
target
focus
lab
procedur
field
trial
start
within
week
start
project
silico
process
identif
suitabl
epitop
design
synthet
peptid
vaccin
vitro
test
vivo
field
trial
entir
process
much
rapid
effici
fact
case
sar
sever
acut
respiratori
syndrom
outbreak
asia
initi
indic
avail
late
genom
sequenc
avail
may
first
result
experiment
vaccin
decemb
extrem
fast
respons
inde
interest
peptid
vaccin
grown
year
especi
indic
good
result
virus
caus
cancer
number
peptid
vaccin
list
clinicaltrialsgov
websit
nih
unit
state
list
present
project
variou
phase
field
trial
relat
anticanc
peptid
vaccin
trial
peptid
vaccin
hiv
influenza
virus
trial
conduct
institut
academia
commerci
firm
major
phase
phase
ii
trial
project
list
phase
iii
includ
enteroviru
alzheim
diseas
major
relat
variou
cancer
project
design
peptid
vaccin
promis
inde
first
success
peptid
vaccin
virul
canin
paroviru
mention
earlier
vaccin
develop
viral
diseas
anim
date
vaccin
licens
human
howev
signific
contribut
made
ration
design
peptid
vaccin
influenza
rotaviru
coronaviru
certain
virus
hypervari
flu
viru
present
greatest
challeng
effort
taken
step
design
univers
flu
vaccin
long
cherish
goal
ideal
could
provid
perman
protect
flu
viru
singl
shot
perhap
booster
shot
everi
year
target
gener
viral
hemagglutinin
protein
conserv
segment
common
flu
strain
provok
effect
antibodi
respons
flu
viru
estim
almost
quarter
half
million
live
lost
annual
flu
accord
world
health
organ
indic
import
vaccin
hepat
c
viru
anoth
viru
high
genom
variabl
tradit
vaccin
method
prove
success
effort
way
develop
synthet
peptid
vaccin
base
ctl
tepitop
determin
viral
core
protein
seen
evok
good
immun
respons
mice
model
peptid
vaccin
multipl
sclerosi
enter
phase
trial
stage
epitop
human
papillomaviru
protein
peptid
vaccin
candid
provid
strong
cellmedi
immun
see
video
abstract
avail
relev
websit
section
epitop
identifi
human
papillomaviru
protein
fig
provid
snapshot
one
peptid
identifi
protein
pentamer
structur
identifi
type
bioinformat
analysi
outlin
combin
chemotherapi
togeth
peptid
vaccin
therapi
also
phase
trial
determin
effect
may
treat
patient
local
advanc
metastat
pancreat
cancer
clinicaltri
websit
list
number
peptid
vaccin
candid
variou
stage
clinic
trial
bioinformat
give
us
valuabl
servic
identifi
potenti
epitop
region
pathogen
safeguard
built
autoimmun
threat
effect
immun
respons
capabl
best
popul
coverag
tradit
method
vaccin
design
take
year
achiev
parallel
result
even
unlik
test
wide
popul
coverag
bioinformat
studi
much
howev
yet
part
total
effort
requir
take
vaccin
comput
marketplac
theoret
deriv
peptid
next
synthes
test
laboratori
mous
model
ensur
predict
immun
respons
actual
occur
administ
synthet
peptid
one
determin
best
carrier
protein
take
care
peptid
fold
vivo
destroy
antibodyantigen
bind
possibl
enhanc
effect
administ
vaccin
suitabl
adjuv
use
use
adjuv
quit
common
well
recogn
adjuv
like
part
cerverix
hpv
vaccin
ad
advantag
use
peptid
vaccin
tradit
whole
protein
vaccin
combin
differ
peptid
one
vaccin
call
multival
vaccin
enabl
wide
coverag
possibl
one
epitop
elicit
adequ
immun
respons
principl
wellknown
gardasil
vlp
vaccin
design
nine
type
human
papillomaviru
childhood
vaccin
known
tripl
antigen
design
diphtheria
tetanu
whoop
cough
toxoid
diphtheria
tetanu
use
along
whole
kill
cell
whoop
cough
exampl
current
use
tradit
vaccin
potenti
multival
vaccin
increas
mani
fold
peptid
vaccin
era
spite
appar
enorm
develop
date
bioinformat
era
vaccin
design
consid
begin
stage
much
need
done
entir
exercis
determin
tcell
bcell
epitop
depend
acut
accuraci
genom
proteom
data
mean
guarante
yet
instanc
still
significantli
larg
number
gene
genom
sequenc
one
constitu
remain
ambigu
exampl
genom
zika
viru
nucleotid
therefor
associ
amino
acid
yet
identifi
certainti
sinc
antibodi
extrem
specif
one
amino
acid
differ
cancel
antibodyantigen
bind
error
databas
make
entir
bioinformat
exercis
vaccin
design
vain
highli
reliabl
data
imper
bioinformat
search
suitabl
vaccin
target
mathemat
statist
techniqu
constitut
major
pillar
bioinformat
exercis
number
differ
techniqu
use
determin
effici
epitop
get
around
effect
mutat
chang
requir
identif
conserv
sequenc
segment
number
alignmentfre
techniqu
facilit
search
robust
techniqu
requir
detail
analysi
combin
techniqu
expect
provid
precis
depend
result
necess
robust
techniqu
perhap
provid
best
result
vaccin
target
analys
fewer
sequenc
need
current
techniqu
best
judg
tri
cope
viral
epidem
epidem
strike
fairli
rapidli
last
month
year
die
either
due
mutat
chang
enough
peopl
acquir
immun
act
deterr
spread
viru
given
fresh
epidem
aris
new
viru
new
strain
old
viru
gather
enough
genom
data
go
normal
dri
wet
lab
foolproof
vaccin
within
time
schedul
outsid
realm
possibl
current
tradit
bioinformat
techniqu
approach
sar
epidem
except
ebola
viru
epidem
could
control
new
vaccin
vaccin
alreadi
design
readi
field
trial
brought
live
use
face
exig
case
futur
epidem
need
much
better
rapidresult
bioinformat
wet
lab
techniqu
contain
viral
attack
world
readi
effect
handl
epidem
pandem
yet
supplementari
data
articl
found
onlin
http
fig
space
fill
model
surfac
protein
pentamer
structur
show
one
peptid
yellow
monom
protein
blue
identifi
surfac
access
conserv
segment
high
epitop
potenti
read
